Haemonetics Corporation (HAE) jumped 0.63 points or 1.58% on strong buying and was last priced at $40.49 per share. The shares saw huge fund flow intraday; a massive $2.34 million made their way in through the upticks but an even bigger $4.07 million made their way out through downticks. As per the last observation, the net money flow stood at $(-1.74) million and the up/down ratio was found to be 0.57. The shares have seen a weekly value change of 1.71% .A block trade was recorded in the company shares with a net money flow of $(-1.52) million. The composite value of the funds in upticks was $0 million and the total value of funds in downticks was $1.52. As can be seen from the data, the block transaction had the up/down ratio of 0.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Haemonetics Corporation rose by 2.47% in the last five trading days and 1.14% for the last 4 weeks. Haemonetics Corporation is up 21.7% in the last 3-month period. Year-to-Date the stock performance stands at 1.14%. Haemonetics Corporation (NYSE:HAE) rose 2.01% or 0.8 points on Wednesday and made its way into the gainers of the day. After trading began at $40.16 the stock was seen hitting $40.83 as a peak level and $40.16 as the lowest level. The stock ended up at $40.66. The daily volume was measured at 572,686 shares. The 52-week high of the share price is $41.41 and the 52-week low is $25.98. The company has a market cap of $2,100 million.
Company has reported several Insider transactions to the SEC, on Dec 14, 2016, Ronald G Gelbman (director) sold 5,683 shares at 40.30 per share price.On Aug 19, 2016, Ronald Merriman (director) sold 4,337 shares at 35.15 per share price.On Aug 16, 2016, Susan Bartlett Foote (director) sold 14,685 shares at 35.34 per share price.
Haemonetics Corporation Last issued its quarterly earnings results on Nov 7, 2016. The company reported $0.38 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $0.35. The company had revenue of $220.30 million for the quarter, compared to analysts expectations of $210.78 million. The companys revenue was up .3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.44 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by The Benchmark Company on Nov 7, 2016 to Hold, Raises Price Target to $ 34 from a previous price target of $32 .
Haemonetics is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collections and plasma collections. The majority of their business is outside the US.